Research Analysts Set Expectations for MIST FY2026 Earnings

Milestone Pharmaceuticals Inc. (NASDAQ:MIST – Free Report) – Research analysts at HC Wainwright upped their FY2026 EPS estimates for shares of Milestone Pharmaceuticals in a report released on Monday, November 16th. HC Wainwright analyst B. Folkes now expects that the company will post earnings per share of ($0.85) for the year, up from their prior forecast of ($0.86). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Milestone Pharmaceuticals’ current full-year earnings is ($0.79) per share. HC Wainwright also issued estimates for Milestone Pharmaceuticals’ Q4 2026 earnings at ($0.26) EPS, FY2027 earnings at ($0.64) EPS, FY2028 earnings at ($0.29) EPS, FY2029 earnings at ($0.11) EPS and FY2030 earnings at $0.47 EPS.

Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report) last announced its quarterly earnings results on Friday, November 13th. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.04. Milestone Pharmaceuticals had a negative net margin of 1,860.76% and a negative return on equity of 435.88%. The firm had revenue of $2.96 million during the quarter, compared to analysts’ expectations of $1.00 million.

Several other analysts also recently weighed in on the company. Cantor Fitzgerald began coverage on Milestone Pharmaceuticals in a report on Thursday, August 20th. They issued an “overweight” rating and a $3.00 target price for the company. Weiss Ratings restated a “sell (e+)” rating on shares of Milestone Pharmaceuticals in a research note on Monday, October 12th. Wall Street Zen raised Milestone Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, November 14th. Finally, Piper Sandler cut their price target on Milestone Pharmaceuticals to $3.00 and set an “overweight” rating on the stock in a research report on Monday. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $5.83.

Read Our Latest Report on Milestone Pharmaceuticals

Milestone Pharmaceuticals Stock Performance

Shares of MIST stock opened at $0.40 on Wednesday. The stock’s 50-day moving average is $0.75 and its two-hundred day moving average is $1.28. The company has a quick ratio of 7.92, a current ratio of 6.27 and a debt-to-equity ratio of 3.25. Milestone Pharmaceuticals has a 1 year low of $0.36 and a 1 year high of $3.06.

Institutional Trading of Milestone Pharmaceuticals

A number of large investors have recently bought and sold shares of the business. HighTower Advisors LLC raised its holdings in shares of Milestone Pharmaceuticals by 100.0% in the second quarter. HighTower Advisors LLC now owns 20,000 shares of the company’s stock valued at $27,000 after buying an additional 10,000 shares during the last quarter. Bay Rivers Group boosted its stake in shares of Milestone Pharmaceuticals by 55.9% during the second quarter. Bay Rivers Group now owns 46,633 shares of the company’s stock worth $62,000 after buying an additional 16,722 shares during the period. Waterloo Capital L.P. acquired a new stake in shares of Milestone Pharmaceuticals during the third quarter worth about $40,000. Pinnacle Wealth Planning Services Inc. acquired a new stake in shares of Milestone Pharmaceuticals during the third quarter worth about $68,000. Finally, ADAR1 Capital Management LLC purchased a new position in shares of Milestone Pharmaceuticals during the second quarter worth about $134,000. Institutional investors and hedge funds own 86.18% of the company’s stock.

About Milestone Pharmaceuticals

(Get Free Report)

Milestone Pharmaceuticals is a biopharmaceutical company focused on developing treatments for cardiovascular conditions. Its work centers on therapies intended to give patients and caregivers options for managing acute heart rhythm episodes outside of a clinical setting. The company’s lead product is etripamil, a short-acting calcium channel blocker formulated as a nasal spray. It is designed for self-administration to treat episodes of paroxysmal supraventricular tachycardia, a condition involving sudden episodes of abnormally fast heart rate.

Recommended Stories

Earnings History and Estimates for Milestone Pharmaceuticals (NASDAQ:MIST)

Receive News & Ratings for Milestone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.